Literature DB >> 3128689

Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.

B J Koopman1, B G Wolthers, J C van der Molen, W van der Slik, R J Waterreus, A van Spreeken.   

Abstract

This study gives a review of the results obtained from biochemical investigations of 20 patients in The Netherlands suffering from cerebrotendinous xanthomatosis, an inborn error of metabolism in bile acid synthesis. Diagnosis can best be established by determining the excretion of urinary bile alcohols, in particular 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha,23,25-pentol, in urine by means of capillary gas chromatography. Measurement of serum cholestanol levels or serum cholestanol/cholesterol ratios, commonly used for establishing cerebrotendinous xanthomatosis, are not reliable. The effectiveness of the different therapies, i.e. administration of bile acids, can be evaluated by monitoring the urinary excretion of bile alcohols. From such investigations it was concluded that cholic acid especially, but also chenodeoxycholic acid are the therapies of choice for the treatment of cerebrotendinous xanthomatosis. All patients, until now diagnosed in The Netherlands were not discovered before the third or fourth decade of life because the characteristic signs only then become manifest clearly. Unfortunately, because sterol storage is almost irreversible, therapy only results in minor improvements of the patient's condition. Therefore early detection of the presence of cerebrotendinous xanthomatosis is desirable so that treatment can start before extensive storage of sterols is a fact. We developed some laboratory assays with the purpose of early detection. One consists of the detection of cerebrotendinous xanthomatosis carriers by subjecting them to oral cholestyramine administration and monitoring the urinary excretion of the bile alcohol 5 beta-cholestane-3 alpha,7 alpha,12 alpha,23,25-pentol before and after treatment. Secondly, a relatively simple screening test for cerebrotendinous xanthomatosis was developed based on an enzymatic assay of 7 alpha-hydroxylated steroids in urine. After suitable modification this assay in principle allows the screening of large populations for the existence of cerebrotendinous xanthomatosis and thus to detect the disease at an earlier stage of life.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128689     DOI: 10.1007/bf01800057

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  58 in total

1.  Cerebrotendinous xanthomatosis (cholestanolosis). Investigations on two sisters and their family.

Authors:  A Schreiner; G Hopen; S Skrede
Journal:  Acta Neurol Scand       Date:  1975-05       Impact factor: 3.209

2.  Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system.

Authors:  J H Menkes; J R Schimschock; P D Swanson
Journal:  Arch Neurol       Date:  1968-07

3.  Cholesterol 7 alpha-hydroxylase.

Authors:  N B Myant; K A Mitropoulos
Journal:  J Lipid Res       Date:  1977-03       Impact factor: 5.922

4.  Quantitation of physiological alpha-tocopherol, metabolites, and related compounds by reversed-phase high-performance chromatography.

Authors:  S K Howell; Y M Wang
Journal:  J Chromatogr       Date:  1982-01-08

5.  Cerebrotendinous xanthomatosis: reduced serum 26-hydroxycholesterol.

Authors:  N B Javitt; E Kok; B Cohen; S Burstein
Journal:  J Lipid Res       Date:  1982-05       Impact factor: 5.922

6.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

7.  Role of the 26-hydroxylase in the biosynthesis of bile acids in the normal state and in cerebrotendinous xanthomatosis. An in vivo study.

Authors:  I Björkhem; O Fausa; G Hopen; H Oftebro; J I Pedersen; S Skrede
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

8.  Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands.

Authors:  R J Waterreus; B J Koopman; B G Wolthers; H J Oosterhuis
Journal:  Clin Neurol Neurosurg       Date:  1987       Impact factor: 1.876

9.  An enzymatic method of determining 7 alpha-hydroxylated bile acids in urine.

Authors:  G Hedenborg; A Norman; K Samuelson
Journal:  Scand J Clin Lab Invest       Date:  1984-12       Impact factor: 1.713

10.  A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.

Authors:  T Setoguchi; G Salen; G S Tint; E H Mosbach
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

View more
  5 in total

1.  Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco-Sjoegren syndrome: a case report.

Authors:  H R Siebner; S Berndt; B Conrad
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

2.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis.

Authors:  J J Cali; C L Hsieh; U Francke; D W Russell
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

3.  Cerebrotendinous xanthomatosis-associated diarrhea and response to chenodeoxycholic acid treatment.

Authors:  Eric P Brass; Bianca M L Stelten; Aad Verrips
Journal:  JIMD Rep       Date:  2020-08-30

4.  Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation.

Authors:  N K Agrawal; Sunny Garg
Journal:  BMJ Case Rep       Date:  2012-09-21

Review 5.  Adulthood leukodystrophies.

Authors:  Wolfgang Köhler; Julian Curiel; Adeline Vanderver
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.